Thomas D. Coates, MD

Professor of Pediatrics

Section Head of Hematology

Director of Sickle/Hemoglobinopathy Program

Image of Thomas D. Coates, MD
Is this your profile? Click to edit

Overview

I primarily work in two areas of basic and translational research: 1) the role of inflammation in the genesis of vascular disease in sickle cell disease; 2) the detection and management of transfusion related iron overload. Our research employs various engineering-intensive methodologies (MRI, laser Doppler flow, digital image analysis, signal processing) to explore the basic mechanisms of sickle cell disease and to measure the effect of various treatment modalities. We use direct measures of microvascular blood flow to monitor the process of vasoocclusion and relate it to simultaneous measures of autonomic nervous system function. These methodologies translate in measurements that can be used to follow patients clinically. In collaboration with members of the Cardiology, Pulmonology, and Radiology Departments at Children’s Hospital Los Angeles, the Departments of Biomedical Engineering and Physiology/Biophysics at the Keck School of Medicine, we devised methods to measure the sickling process in human sickle cell subjects and relate these measurements to clinical factors that modulate disease severity.

Research Funding

  • Multimodal biophysical markers of vascular disease in hemoglobinopathies
    NIH · U01HL117718 · Aug 15, 2013 – May 31, 2019 · Role: Principal Investigator
  • SOUTHERN CALIFORNIA BLOOD SAFETY SURVEILLANCE PROGRAM IN HEMATOLOGICAL DISORFERS
    NIH · U50DD000874 · May 1, 2012 – Apr 30, 2015 · Role: Principal Investigator
  • Basic and Translational Research Program
    NIH · U54HL090511 · Jun 15, 2008 – Feb 28, 2013 · Role: Principal Investigator
  • Research Initiatives for the Preventions of Complications of Thalassemia
    NIH · U01DD000309 · Sep 30, 2007 – Sep 29, 2012 · Role: Principal Investigator
  • Human models of sickle cell vascular damage
    NIH · R01HL071801 · Jul 8, 2003 – Jun 30, 2008 · Role: Principal Investigator
  • GRANULES AND ORGANELLES AND LEUKOCYTE ACTIVATION
    NIH · R01AI023547 · Sep 1, 1985 – Nov 30, 1999 · Role: Principal Investigator

Publications

  • Too little, too late? The burden of delayed care in NTDT. Blood Adv. 2026 Sep 22; 10(18):6164-6166.. View in PubMed
  • Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2026 09 12; 408(10559):1010-1018.. View in PubMed
  • Chronic Anemia Is Associated With Subclinical Myocardial Fibrosis in α-Τhalassemia Intermedia. Am J Hematol. 2026 Sep 01.. View in PubMed
  • A Community-Based Intervention to Increase PrEP Initiation and Reduce Internalized Stigma: A Randomized Trial Among Black Sexual Minority Men in Prince George’s County, Maryland. AIDS Patient Care STDS. 2026 Jul 29; 10872914261470132.. View in PubMed
  • Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta-Thalassemia Trait. Am J Hematol. 2026 Oct; 101(10):2659-2661.. View in PubMed
  • Addressing Obstetric and Gynecologic Needs in Thalassemia. O G Open. 2026 Aug; 3(4):e181.. View in PubMed
  • Analysis of Intraoperative Complications and Outcomes Associated With Obesity During Elective Laparoscopic Cholecystectomy. World J Surg. 2026 Aug; 50(8):2299-2305.. View in PubMed
  • Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias. Blood Adv. 2026 Jun 04.. View in PubMed
  • Chronic Anemia Patients Demonstrate Diffuse Demyelination. Am J Hematol. 2026 Aug; 101(8):1878-1890.. View in PubMed
  • Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study. Haematologica. 2026 Apr 16.. View in PubMed